MiNK Therapeutics, Inc.
About MiNK Therapeutics, Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$12.5M
- Total assets
- $14.2M
- Market cap
- $59.1M
- Operating margin
- -7013.8%
- Net margin
- -6931.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $180.2K
- Operating expenses
- $12.8M
- Operating income
- -$12.6M
- Net income
- -$12.5M
- EPS (basic)
- $-2.93
- EPS (diluted)
- $-2.93
Balance sheet
- Total assets
- $14.2M
- Current assets
- $13.8M
- Total liabilities
- $28.5M
- Current liabilities
- $13.0M
- Shareholders’ equity
- -$14.2M
Cash flow
- Operating cash flow
- -$5.9M
- Investing cash flow
- -$8.8M
- Financing cash flow
- $14.7M
- Net cash flow
- $13.4K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $59.1M
- EPS (diluted)
- $-2.93
- Shares outstanding
- 4.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $12.5M.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review MiNK Therapeutics, Inc..
Write a review
News about MiNK Therapeutics, Inc.
News & sentiment via Polygon.io
